Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7202836 | 0.83 | RIPK2 (0.35) | RIPK2 | |
| SCHEMBL7202112 | 0.82 | RIPK2 (0.34) | RIPK2 | |
| SCHEMBL6972984 | 0.80 | RIPK2 (0.33) | RIPK2 | |
| SCHEMBL7201948 | 0.80 | RIPK2 (0.32) | RIPK2 | |
| SCHEMBL8582249 | 0.80 | RIPK2 (0.33) | RIPK2 | |
| SCHEMBL564135 | 0.74 | ADRA2A (0.55) | — | |
| Hydrochloric Acid SCHEMBL9341170 | 0.72 | ADRA2A (0.53) | — | |
| SCHEMBL7202913 | 0.71 | ADRA2A (0.62) | — | |
| SCHEMBL7202918 | 0.69 | — | — | |
| SCHEMBL1669608 | 0.67 | ADRA2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998023612-A1 | 2-IMIDAZOLINYLAMINOBENZOTHIAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| WO-1998023612-A1 | 2-IMIDAZOLINYLAMINOBENZOTHIAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | RIPK2 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.